Clinical Trials

YolTech Reports Positive Interim Data For YOLT 202 In Alpha 1 Antitrypsin Deficiency

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with ...

 February 23, 2026 | News

Takeda Reports Positive Phase 3 KEPLER Data For ENTYVIO In Pediatric Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...

 February 23, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company,  announced a partnership with Accord Healthcare to provide access to ANKTI...

 February 23, 2026 | News

Deciphera Pharmaceuticals Secures FDA NDA Acceptance For Tirabrutinib In R R PCNSL

-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...

 February 20, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

 February 20, 2026 | News

Mammotome Introduces In Room MRI Guided Breast Biopsy System To Improve Clinical Workflow

Mammotome, a Danaher company, announces the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System, the industry's first system designed t...

 February 19, 2026 | News

Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...

 February 19, 2026 | News

Eli Lilly And Company Reports Statistically Significant Event Free Survival Benefit With Selpercatinib In Early Stage RET Fusion Positive NSCLC

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...

 February 18, 2026 | News

Lilac Biosciences And Soin Neuroscience Partner To Advance RNA Based Biomarkers For Pain Research

- Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical too...

 February 17, 2026 | News

Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer

Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...

 February 16, 2026 | News

HanchorBio Secures FDA Orphan Drug Designation For HCB101 In Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer  HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnolog...

 February 16, 2026 | News

Alphamab Oncology Advances JSKN003 Into Phase III Trial For HER2 Positive Advanced Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005...

 February 16, 2026 | News

Ribo And Ribocure Sign Global Licensing Deal With Madrigal For Six siRNA Programmes In MASH

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure")  announced that they have entere...

 February 13, 2026 | News

ArkBio Receives FDA IND Clearance For AK3280 Phase Two Trial In Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) applicat...

 February 13, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close